Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Ionis Pharmaceuticals

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Sunday shared results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG), a condition characterized by dangerously high triglyceride (fat) levels.

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released topline results on Monday from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive, and often fatal neurological condition.

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG).

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter.

inkl

Read news from The Economist, FT, and more,
with one subscription

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

Recap: Ionis Pharmaceuticals Q1 Earnings

Recap: Ionis Pharmaceuticals Q1 Earnings

Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Expert Ratings For Ionis Pharmaceuticals

Expert Ratings For Ionis Pharmaceuticals

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter:

BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?

BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?

Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12 months that could unlock value, according to BofA Securities.

Organisations

European Commission

BofA Securities

B of A Securities

Coinbase Global

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play